Summary & Overview
HCPCS Level II K1035: Molecular Diagnostic Test Reader for Self-Testing
HCPCS Level II code K1035 denotes a molecular diagnostic test reader marketed for nonprescription, self-administered and self-collected use that is FDA approved, authorized, or cleared. The code covers devices that enable patients to collect specimens themselves and obtain molecular test interpretations outside clinical settings. This category is important as at-home diagnostics expand access to infectious disease and other molecular testing while raising questions about coverage pathways, coding consistency, and claims processing nationally.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what K1035 represents, how it fits into service lines for at-home molecular testing, and the typical sites of service. The publication highlights billing and policy considerations relevant to payers, common modifier usage, and areas where data were not available in the input. It also outlines what to expect in related content: reimbursement benchmarks, payer-specific coverage trends, and clinical context for patient-collected molecular diagnostics.
The report is written for a national audience seeking clarity on coding and administrative handling of at-home molecular diagnostic readers. Data not available in the input are noted where applicable; the document focuses on clear, actionable descriptions of code scope, service type, and operational setting for stakeholders involved in billing, coverage, and clinical integration.
Billing Code Overview
HCPCS Level II code K1035 describes a molecular diagnostic test reader intended for nonprescription, self-administered and self-collected use, and that is FDA approved, authorized, or cleared. The device interprets molecular test results provided by a patient-collected specimen and is designed for use without a prescription.
Service type: Molecular diagnostic device for patient self-testing
Typical site of service: Home or other non-clinical self-care settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving an FDA-authorized, over-the-counter molecular diagnostic test for self-collection and self-administration at home to detect a respiratory pathogen (for example, SARS-CoV-2 or influenza). The patient obtains the test from a retail pharmacy or is provided the device by a clinic. The workflow begins with the patient reviewing manufacturer instructions, performing a nasal or saliva self-collection, running the assay in the approved reader device, and receiving an on-device result. The patient may report results to their primary care clinician or an occupational health office for return-to-work decisions. If a positive result is obtained, the clinician documents the result in the medical record and may order confirmatory laboratory-based molecular testing or initiate clinical management and isolation guidance. Typical sites of service include home/self-care, retail pharmacy, and occasionally outpatient primary care or urgent care when device demonstration or supervised self-collection is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to support the testing (for example, complex documentation or extensive counseling) substantially exceeds typical requirements. |
23 |